Since ovarian tumor cells with the co-upregulation of FAK and Myc are more sensitive to the combination of VS-603 and JQ1 than their counterparts (Figure 7), the aberrant expression of FAK and Myc likely serves as promising biomarkers for identifying the corresponding patient cohort in the clinic. This evidence concerns the gene PTK2 and ovarian neoplasm.